semaglutide and alopecia Study Offers More Evidence That Ozempic Could Cause Hair Loss New emerging evidence suggests that

10.1016/S0140-6736(23)01185-6 35

Convenience, patient acceptance, adherence potential, and the growing evolution of oral GLP-1s may further accelerate that trend

The on-demand pathway is designed to reduce the friction of staying on treatment - a meaningful problem in the GLP-1 market, where medication discontinuation rates are high and one of the most common reasons patients stop is difficulty getting timely prescription refills

That trial demonstrated statistically significant improvement in growth velocity in patients receiving sermorelin versus placebo over a 6-month treatment period, with a mean increase in annualized growth velocity of approximately 3.9 cm/year in the treated group compared with 1.2 cm/year in controls [4]